Production of monocyte chemoattractant protein‐1 in amyotrophic lateral sclerosis

The presence of activated microglia in the spinal cord of amyotrophic lateral sclerosis (ALS) patients is usually accompanied by inflammatory biochemical changes, but these are largely unexplored. Monocyte chemoattractant protein‐1 (MCP‐1) is critical for recruitment of inflammatory cells of monocytic lineage after inflammation or injury to the central nervous system. MCP‐1 concentrations were measured by an enzyme‐linked immunosorbent assay in the cerebrospinal fluid (CSF) and the serum of 27 patients with ALS and 30 patients with noninflammatory neurological diseases. In ALS, circulating MCP‐1 levels were significantly increased in the serum and particularly in the CSF. Immunoreactivity for MCP‐1 in ALS spinal cord was detected mostly in astrocytes but also in microglia, neurons, and within the vasculature of the cord. Our findings suggest a role for MCP‐1 as an important molecular mediator of the injury response in ALS. Muscle Nerve, 2005

[1]  S. Appel,et al.  Increased lipid peroxidation in sera of ALS patients , 2004, Neurology.

[2]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[3]  G. Deuschl,et al.  Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration , 2003, Journal of Neuroimmunology.

[4]  P. Mcgeer,et al.  Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[5]  N. Berman,et al.  Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. , 2002, Brain research. Molecular brain research.

[6]  R. Doms,et al.  Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons , 2000, Neuroscience.

[7]  S. Takashima,et al.  Developmental expression of monocyte chemoattractant protein-1 in the human cerebellum and brainstem , 1999, Brain and Development.

[8]  B. Rollins,et al.  Monocyte chemoattractant protein-1. , 1999, Chemical immunology.

[9]  W. Kelder,et al.  β‐Chemokines MCP‐1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus–associated dementia , 1998 .

[10]  C. Brosnan,et al.  MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study , 1998, Journal of Neuroimmunology.

[11]  J. Szaflarski,et al.  Hypoxic-Ischemic Injury Induces Monocyte Chemoattractant Protein-1 Expression in Neonatal Rat Brain , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  T. Miyakawa,et al.  Identification of monocyte chemoattractant protein‐1 in senile plaques and reactive microglia of Alzheimer's disease , 1997, Psychiatry and clinical neurosciences.

[13]  C. Brosnan,et al.  Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. , 1996, Journal of immunology.

[14]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[15]  B. Rollins,et al.  JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. , 1992, Circulation research.

[16]  D. Troost,et al.  Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis , 1990, Neuropathology and applied neurobiology.